Each vial of powder contains highly purified menotrophin (human menopausal gonadotrophin, HMG) corresponding to 1200IU human follicle stimulating hormone (FSH) and 1200IU human luteinising hormone (LH) activity.

Human Chorionic Gonadotrophin (hCG), a naturally occurring hormone in postmenopausal urine, is present in MENOPUR and contributes to the overall luteinizing hormone activity.

Menotrophin is produced from human urine.

For subcutaneous use only.

The powder must be reconstituted immediately with the solvent provided prior to use (see section 6.6). The reconstituted solution is for multiple injections and can be used for up to 28 days. Menopur 1200IU powder and solvent for solution for injection is indicated for the treatment of female and male infertility in the following groups of patients:

- Anovulation, including polycystic ovarian disease (PCOD) in women who have been unresponsive to treatment with clomiphene citrate.
- Women undergoing controlled ovarian hyperstimulation: MENOPUR can induce the development of multiple follicles for assisted reproductive technologies (ART) (e.g. in vitro fertilisation/embryo transfer (IVF/ET), gamete intra-fallopian transfer (GIFT) and intracytoplasmic sperm injection (ICSI)).
- Hypogonadotrophic hypogonadism in men: MENOPUR may be given in combination with human chorionic gonadotrophin (e.g. Choragon) for the stimulation of spermatogenesis. Patients with primary testicular failure are usually unresponsive.

MENOPUR is available in the following containers and pack sizes:

Powder: 2 ml colourless glass (type I glass) vial with rubber stopper closed with a cap.
Solvent: 1 ml pre-filled syringe (type I glass) with rubber (type I) tip cap and plunger stopper , without needle.

Each pack contains 1 vial of powder, 2 pre-filled syringes with solvent for reconstitution, 1 needle for reconstitution and 18 disposable syringes for administration graduated in FSH/LH units with pre-fixed needles.